Lawrence Bruno's most recent trade in Core Laboratories N.V. was a trade of 204,340 Performance Shares done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 204,340 | 204,340 | - | - | Performance Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 180,722 | 0 | - | - | Performance Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 180,722 | 370,119 (0%) | 0% | 0 | Common Stock | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.03 per share. | 31 Dec 2025 | 112,681 | 257,438 (0%) | 0% | 16.0 | 1,806,276 | Common Stock |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 202,764 | 202,764 | - | - | Performance Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 69,574 | 0 | - | - | Performance Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 69,574 | 232,777 (0%) | 0% | 0 | Common Stock | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 31 Dec 2024 | 43,380 | 189,397 (0%) | 0% | 17.3 | 750,908 | Common Stock |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 155,126 | 155,126 | - | - | Performance Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 91,212 | 0 | - | - | Performance Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 91,212 | 138,410 (0%) | 0% | 0 | Common Shares | |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.27 per share. | 31 Dec 2022 | 35,892 | 102,518 (0%) | 0% | 20.3 | 727,531 | Common Shares |
| Core Laboratories N.V. | Lawrence Bruno | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 127,424 | 127,424 | - | - | Performance Shares |